Welcome to our dedicated page for Maxcyte SEC filings (Ticker: MXCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The MaxCyte, Inc. (NASDAQ: MXCT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Delaware corporation with common stock listed on The Nasdaq Stock Market LLC under the symbol MXCT, MaxCyte uses SEC reports to communicate material events, financial results, capital market actions and governance changes related to its cell-engineering business.
Investors researching MXCT can use this page to review Form 8-K filings that describe significant developments. Recent 8-Ks have covered preliminary unaudited financial results, quarterly earnings releases, an operational restructuring and workforce reduction plan, and leadership changes such as the departure of the chief commercial officer. Another 8-K details MaxCyte’s application to cancel admission of its common stock to trading on the AIM market of the London Stock Exchange, while confirming that its Nasdaq listing remains in place.
MaxCyte’s SEC filings also reference its use of non-GAAP financial measures, including EBITDA, Adjusted EBITDA and Non-GAAP Gross Margin, and explain how management uses these metrics alongside GAAP results. Filings describe the company’s revenue composition, distinguishing between core business revenue and Strategic Platform License (SPL) program-related revenue, and discuss expectations for cost structure and cash resources.
On Stock Titan, these documents are supplemented with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly understand topics such as restructuring costs, expected annualized savings, revenue guidance and capital position. Real-time updates from EDGAR ensure that new 8-Ks, 10-Qs and 10-Ks appear promptly, while insider-related disclosures on forms such as Form 4 can be accessed to track reportable transactions by directors and officers. This combination of original filings and AI-generated insights offers a structured way to analyze MaxCyte’s regulatory history and ongoing reporting.
Douglas Richard, a director of MaxCyte, Inc. (MXCT), purchased shares on 08/13/2025. The Form 4 reports an acquisition of 80,000 shares of common stock, increasing his reported beneficial ownership to 230,577 shares held directly. The filing shows a reported price of $1.388 per share with a footnote stating the shares were bought in multiple transactions at prices ranging from $1.30 to $1.40 and that the reporter will provide a detailed breakdown on request. The form is signed by an attorney-in-fact for the reporting person.
Brooke William W, a director of MaxCyte, Inc. (MXCT), reported a purchase of 50,000 shares of common stock on 08/13/2025 at $1.29 per share, bringing his direct beneficial ownership to 150,879 shares. The Form 4 shows no derivative holdings and no amendment date. The filing was signed by an attorney-in-fact, David Sandoval, on 08/13/2025.
MaxCyte, Inc. reported the departure of Ali Soleymannezhad from his role as Chief Commercial Officer. The company states his separation is governed by an Amended and Restated Severance Agreement dated July 1, 2024.
Under that agreement, Mr. Soleymannezhad will receive his base salary for nine months and contributions toward COBRA health care continuation for the nine-month severance period, provided he executes and complies with the agreement's release of claims. The filing references the Severance Agreement filed as exhibit 10.2 to the Company’s Quarterly Report for the quarter ended March 31, 2025. No salary amounts, successor information, or additional operational or financial details were disclosed.
Form 8-K overview: On 25 June 2025, MaxCyte, Inc. ("the Company") filed a Current Report to disclose that it has applied to the London Stock Exchange to cancel admission of its common stock to trading on AIM. The filing designates the action as an "Other Event" under Item 8.01.
Key dates: The last day of AIM trading will be 25 June 2025, and the AIM delisting becomes effective at 7:00 a.m. U.K. time on 26 June 2025.
Continuing listing: The Company explicitly states that the AIM delisting "has no impact on the Company’s Nasdaq listing," and the shares will remain traded on the Nasdaq Global Select Market under ticker MXCT.
Additional disclosure items: No financial statements, earnings data, or major transactions are included. One exhibit (Ex. 104) accompanies the filing, containing the Inline XBRL cover page.
Implications disclosed: The filing is focused solely on the administrative change in listing status; it does not describe strategic rationale, cost implications, or future capital-markets plans. Investors trading on Nasdaq are unaffected according to the Company. U.K.-based investors will cease to have on-exchange access via AIM once the delisting takes effect.
MaxCyte, Inc. (MXCT) Form 4 – Insider equity grant
On 06/18/2025 non-employee director Rekha Hemrajani received her annual board compensation grant: (i) 29,210 restricted stock units (RSUs) and (ii) a stock option for 50,790 shares with a $2.11 exercise price, expiring 06/17/2035. The RSUs and options were issued under the company’s established Equity Grant Policy for outside directors.
The RSUs convert 1-for-1 into common shares and will vest in full on 06/18/2026, subject to continuous service. No cash was paid for the RSUs (code “A”; price $0). Following the grant, Hemrajani’s direct beneficial ownership increased to 50,577 common shares. No shares were sold or disposed of.
Because the grant is routine, the filing does not necessarily reflect incremental insider sentiment. Nonetheless, it maintains alignment between the director and shareholders and sets a strike price reference at $2.11; upside exists if MXCT trades above that level before 2035.
MaxCyte, Inc. (MXCT) – Form 4 insider filing
Non-employee director Stanley C. Erck reported two compensation-related equity grants dated 18 Jun 2025:
- 29,210 Restricted Stock Units (RSUs) acquired at $0 cost. Each RSU converts to one common share and is scheduled to vest on 18 Jun 2026, conditional on Mr. Erck’s continued board service.
- Stock option for 50,790 shares with an exercise price of $2.11 per share and an expiration date of 17 Jun 2035. The filing classifies the grant as an acquisition (“A”).
Post-transaction, Mr. Erck reports 298,328 common shares held directly. Option holdings now total 50,790 derivative securities.
The filing notes that the equity awards were made under the company’s Equity Grant Policy for non-employee directors. No open-market purchases or sales were disclosed, and there is no indication of a Rule 10b5-1 trading plan for this transaction.
Investor takeaway: The activity reflects routine annual board compensation, modestly increasing insider ownership without immediate cash outlay. It does not signal a change in fundamental outlook or corporate strategy.
FAQ
What is the current stock price of Maxcyte (MXCT)?
What is the market cap of Maxcyte (MXCT)?
